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ARTICLE
Macropinocytosis confers resistance to therapies
targeting cancer anabolism
Vaishali Jayashankar1 & Aimee L. Edinger1✉
Macropinocytic cancer cells scavenge amino acids from extracellular proteins. Here, we show
that consuming necrotic cell debris via macropinocytosis (necrocytosis) offers additional
anabolic benefits. A click chemistry-based flux assay reveals that necrocytosis provides not
only amino acids, but sugars, fatty acids and nucleotides for biosynthesis, conferring resis-
tance to therapies targeting anabolic pathways. Indeed, necrotic cell debris allow macro-
pinocytic breast and prostate cancer cells to proliferate, despite fatty acid synthase inhibition.
Standard therapies such as gemcitabine, 5-fluorouracil (5-FU), doxorubicin and gamma-
irradiation directly or indirectly target nucleotide biosynthesis, creating stress that is relieved
by scavenged nucleotides. Strikingly, necrotic debris also render macropinocytic, but not non-
macropinocytic, pancreas and breast cancer cells resistant to these treatments. Selective,
genetic inhibition of macropinocytosis confirms that necrocytosis both supports tumor
growth and limits the effectiveness of 5-FU in vivo. Therefore, this study establishes
necrocytosis as a mechanism for drug resistance.
https://doi.org/10.1038/s41467-020-14928-3 OPEN
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Because oncogenic mutations constitutively drive anabolism,cancer cells require continuous access to extracellular nutri-ents for their survival1. At the same time, nutrient delivery to
tumor cells is limited by abnormal, leaky vasculature, and high
interstitial pressure that collapses blood vessels, further compro-
mising perfusion. These limitations make tumor cells reliant on the
catabolic process of autophagy2. While macroscopic tumor growth
depends on autophagy because it keeps tumor cells alive, tumor cell
catabolism produces atrophy, not growth. For nutrient-deprived
tumor cells to proliferate, they must complement nutrient recycling
via autophagy with the scavenging of macromolecules from the
microenvironment1. Because scavenged nutrients are derived from
extrinsic, rather than intrinsic, macromolecules, they can support
proliferation as well as survival3. Macropinocytosis is one scaven-
ging strategy1. Macropinosomes form when plasma membrane
ruffles close on themselves and pinch off, producing large, uncoated
intracellular vesicles encapsulating extracellular proteins, fluid, and
small particles. Oncogenic mutations in RAS or activation of the
phosphoinositide 3-kinase (PI3 kinase) pathway can drive macro-
pinocytosis3–5. The RAC1 activation required for ruffling can occur
via phosphatidylinositol-(3,4,5)-trisphosphate (PIP3) dependent
guanine nucleotide exchange factors6, downstream of AMP-
sensitive kinase (AMPK)3, or through alternative mechanisms.
PIP3 is also required for macropinosome closure7. Pancreas and
prostate cancers bearing oncogenic mutations in KRAS or PTEN,
respectively, use amino acids derived from engulfed extracellular
proteins to proliferate in nutrient-limiting environments3,4,8–10. PI3
kinase pathway mutations are also common in breast cancer11.
While macropinocytosis has not yet been shown to support breast
cancer anabolism, this cancer class would likely benefit from
macropinocytosis. Desmoplasia, excessive fibrosis that limits per-
fusion, creates a selective pressure that would favor the outgrowth
of breast cancer cells that are capable of nutrient scavenging12.
Necrosis is a common feature of invasive breast cancer; breast
tumor growth often outstrips the vasculature leaving tumor cells
nutrient-limited13. Necrotic cell debris consumed via macro-
pinocytosis (necrocytosis) could sustain tumor cell anabolism in
poorly perfused areas where nutrients are limiting3.
Many standard-of-care chemotherapeutics kill tumor cells by
creating nutrient stress14. Some of these agents target enzymes
required for de novo nucleotide synthesis, while others cause
DNA damage that increases the demand for nucleotides for DNA
repair15. Autophagy can supply cells with recycled nucleotides
and confers resistance to both chemotherapy and radiation16.
Amino acids provided by macropinocytosis might also confer
resistance to therapies that increase the demand for nucleotides
by fueling de novo nucleotide synthesis pathways. If macro-
pinocytic cells could directly scavenge nucleotides, even greater
protection might be observed because the energetic cost of
nucleotide synthesis would be avoided. Necrocytosis could in
principle supply the end-products of all biosynthetic pathways.
Because nutrients supplied by necrocytosis would be derived from
cell-extrinsic sources rather than catabolism, they might allow
cells to proliferate in the presence of standard-of-care che-
motherapies that target biosynthetic pathways.
Here we demonstrate that breast cancer cell lines with onco-
genic mutations that activate KRAS or the PI3K pathway fuel
proliferation in nutrient-limiting conditions using not just amino
acids, but also sugars, lipids, and nucleotides scavenged via
macropinocytosis. Moreover, necrocytosis affords dramatic
resistance to a range of standard-of-care therapies that target the
metabolic dependencies of cancer cells; albumin supplementation
does not provide similar protection. Finally, the use of a genetic
strategy that more selectively disables macropinocytosis in tumor
cells reveals that macropinocytosis drives both tumor growth and
drug resistance in vivo.
Results
Macropinocytosis supports anabolism in breast cancer cells.
Although growth factors can induce macropinocytosis in breast
cancer cells17, it was unclear whether breast cancer cells are
constitutively macropinocytic or whether macropinocytosis can
support breast cancer proliferation when nutrients are limiting.
To begin to address these questions, 70 kD dextran uptake was
measured in a panel of breast cancer cell lines with activating
mutations in KRAS or PIK3CA or with PTEN loss. Because
nutrient stress is required to induce macropinocytosis in some
cells3, experiments were conducted in both complete and
nutrient-deficient medium containing 1% the normal level of
amino acids and glucose (1% AA/gluc). EIPA (5-[N-ethyl-N-
isopropyl] amiloride), a Na+/H+ exchanger (NHE) inhibitor
that blocks macropinocytosis but not receptor-mediated
endocytosis3,18, was used to confirm that dextran uptake occur-
red via macropinocytosis. Immortalized but non-transformed
hTERT-HME1 mammary epithelial cells and MCF10A cells did
not exhibit macropinocytosis in complete medium, but dextran
uptake was stimulated by nutrient deprivation (Fig. 1a and
Supplementary Fig. 1a). Similar to pancreas, bladder, colorectal,
and lung cancer cell lines with RASmutations3,4,19, KRAS-mutant
MDA-MB-231 breast cancer cells were robustly macropinocytic
in complete medium (Fig. 1a and Supplementary Fig. 1a). MCF-7
and T-47D cells with PIK3CAE545K and PIK3CAH1047R muta-
tions, respectively, also efficiently took up high molecular weight
dextran in both complete and 1% AA/gluc medium. Indeed,
although PIK3CB was found to be required for growth factor-
stimulated macropinocytosis17, oncogenic mutations in PIK3CA
were sufficient to induce constitutive macropinocytosis in murine
embryonic fibroblasts (MEFs) and non-transformed MCF10A
cells20 (Supplementary Fig. 1b, c) confirming that PI3Kα activa-
tion can drive macropinocytosis. Hs578T breast cancer cells carry
a mutation in the PI3K regulatory subunit p85α, PIK3R1, that
leads to hyper-activation of the PI3K pathway. Like MCF-7 and
T-47D cells, Hs578T cells exhibited constitutive macropinocytosis
(Fig. 1a and Supplementary Fig. 1a). PTEN-null BT-459 breast
cancer cells exhibited constitutive macropinocytosis similar to
PTEN-deficient prostate cancer cells3, while PTEN-deficient
MDA-MB-468 cells were contextually macropinocytic in low-
nutrient medium (Fig. 1a and Supplementary Fig. 1a). In contrast,
PTEN-null HCC1569 cells did not exhibit macropinocytosis even
under nutrient stress, although they were capable of performing
macropinocytosis when stimulated with phorbol 12-myristate 13-
acetate (PMA), an inducer of robust macropinocytosis in multiple
cell types (Fig. 1a and Supplementary Fig. 1a, d). 4T1 murine
mammary carcinoma cells, a commonly used model for triple-
negative breast cancer21, were also evaluated. While not macro-
pinocytic in complete medium, glucose restriction or direct
activation of AMPK with A769662 stimulated macropinocytosis
in 4T1 cells similar to results in human MDA-MB-468 triple-
negative breast cancer cells (Fig. 1a and Supplementary Fig. 1a, e)
and Pten-deficient MEFs3. EIPA-sensitive 70 kD FITC-Ficoll
uptake was observed in orthotopic, syngeneic 4T1 tumors in
female BALB/c mice indicating that AMPK activation or other
signals are sufficient to trigger macropinosome formation in vivo
(Fig. 1b)22. Together, these results (Fig. 1a, b and Supplementary
Fig. 1a–e) suggest that many breast tumors are macropinocytic.
Prostate and pancreas cancer cell lines can fuel proliferation in
amino acid-limiting conditions with macropinocytosis3,4,9. In most
studies that measure the anabolic value of macropinocytosis,
albumin is provided as a macropinocytic fuel source because it is
one of the most abundant extracellular proteins in tumors. However,
physiological levels of bovine serum albumin (BSA, 5%) did not
support the proliferation of constitutively macropinocytic MCF-7 or
T-47D cells or non-macropinocytic HCC1569 cells in medium
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containing 1% of the normal amount of amino acids (1% AA,
Fig. 1c). BSA can only provide amino acids at the ratio they are
present in its primary sequence, and these levels may not be ideal to
support global protein synthesis. Necrotic cell debris is small enough
to be consumed by macropinocytosis, a process we have labeled
necrocytosis3. Upon digestion in the lysosome, dead cell fragments
will provide amino acids at the ratio they are present in cellular
proteins. As expected, breast cancer cells were able to consume
CFSE-labeled necrotic debris, but not larger diameter apoptotic cells
(Fig. 1d–f). Necrotic cell debris supported the proliferation of
macropinocytic MCF-7 and T-47D breast cancer cells in 1% AA
medium even when provided at a 25-fold lower concentration than
BSA (0.2% protein, Fig. 1c). Non-macropinocytic HCC1569 cells did
not benefit from supplementation with necrotic debris. Moreover,
apoptotic cells that are too large to be consumed by macropino-
cytosis did not support the proliferation of macropinocytic MCF-7
breast cancer cells under similar conditions (Fig. 1f, g). These studies
confirm that the rate of macropinocytic flux in amino acid-limited
breast cancer cells is sufficient to support proliferation, that necrotic
cell debris is a superior fuel source compared to albumin, and that
the nutrients contained in necrotic debris are only accessible to
macropinocytic cells.
Measuring macropinocytic flux using click chemistry. For
macropinocytosed proteins to support protein synthesis in a
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Fig. 1 Macropinocytosis supports proliferation in nutrient-deprived breast cancer cells. a Dextran index in complete medium (CM) or 1% AA/gluc
medium. Gray (contextual), blue (constitutive), and red (non-macropinocytic) cell lines. Statistics compare cells ± EIPA (50 μM). Using an unpaired, two-
tailed t-test, ***P≤ 0.001; no asterisk, P > 0.05; 40 cells were evaluated from n= 3 except for MCF10A where n= 2. In box plots, the center line is the
median, the box is delimited by the 25th and 75th percentile, and whiskers represent minimum and maximum values. b FITC-Ficoll uptake in orthotopic 4T1
tumors ± EIPA (10mg/kg). Ficoll field index calculated from 15 fields from four tumor sections; shown in white. Using an unpaired, two-tailed t test, ***P≤
0.001. c Proliferation of macropinocytic MCF-7 and T-47D cells or non-macropinocytic HCC1569 cells in 1% AA medium ± albumin (5%) or necrotic debris
(0.2% protein). Mean ± SD, n= 3. Using a one-way ANOVA and Dunnett’s correction, *P≤ 0.05, ***P≤ 0.001, ns, not significant P > 0.05. d IL-3 was
withdrawn from CFSE-labeled FL5.12 cells for 24 or 72 h to produce apoptotic cells or necrotic cell debris, respectively. e Uptake of CFSE-labeled necrotic
debris in 1% AA/gluc ± EIPA (50 μM). f As in e but with CFSE-labeled apoptotic cells. In e, f cells were also stained with LysoTracker Red (LTR). Percent of
cell area positive for CFSE in white. Using an unpaired, two-tailed t-test, ***P≤ 0.001; ns, not significant, P > 0.05; n= 40 cells from two independent
experiments. gMCF-7 cell proliferation in 1% AA ± apoptotic cells (1% protein) or necrotic cell debris (0.2% protein). Proliferation was evaluated at 48 h to
avoid secondary necrosis of apoptotic cells. Mean ± SD, n= 3. Using a one-way ANOVA and Dunnett’s correction, ns, not significant, P > 0.05. Scale bars,
10 µm (d) or 20 µm (b, e and f).
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nutrient-deprived cell, four processing steps are required: uptake,
trafficking to the lysosome, lysosomal proteolysis, and export of
the monomeric amino acids to the cytosol1. The transfer of iso-
topically labeled amino acids from the necrotic cells’ proteome
into the macropinocytic cells’ proteome requires that each of
these steps is completed and is therefore a holistic measurement
of macropinocytic flux3. Although highly specific and quantita-
tive, this approach requires relatively expensive labeling medium
and proteomics capabilities that are not readily accessible to all
laboratories. Copper-catalyzed azido-alkyne cycloaddition, a
common form of “click” chemistry23, offers an alternative strat-
egy for measuring macropinocytic flux (Fig. 2a). A “clickable”
alkynyl form of methionine, homopropargylglycine (HPG), is
incorporated into proteins, commercially available, and inex-
pensive24. HPG-labeled proteins are readily visualized with
Alexa488-streptavidin after clicking on azido-biotin (Fig. 2b, c
and Supplementary Fig. 2a).
To validate this strategy for measuring macropinocytic flux
(Fig. 2a), HPG-labeled FL5.12 murine hematopoietic cells were
generated (Fig. 2b). FL5.12 cells are ideally suited for creating
labeled, necrotic debris due to their rapid growth (doubling time
of 12 h) and their strict dependence on exogenous IL-3 for
survival which allows for the induction of apoptosis and
secondary necrosis without the application of noxious chemicals.
While adding free HPG to amino acid-deprived MCF-7
(macropinocytic) or HCC1569 (non-macropinocytic) cells
resulted in robust labeling of cytosolic and nuclear proteins in
both cell types (Fig. 2c), only macropinocytic MCF-7 cells were
labeled when HPG was provided in the form of labeled necrotic
debris (Fig. 2d–f). At 1 h, HPG labeling was confined to
macropinosome-like structures distributed throughout the cyto-
sol (Fig. 2d). Confirming that necrotic debris was consumed via
macropinocytosis, the HPG-positive structures in MCF-7 cells
were eliminated by EIPA, and no HPG labeling was observed in
non-macropinocytic HCC1569 cells incubated with HPG-labeled
necrotic debris (Fig. 2d, e). After 24 h, the HPG signal in MCF-7
cells was distributed throughout the nucleus and cytosol,
producing a pattern similar to that seen in MCF-7 cells labeled
with free HPG (Fig. 2c, g). Similar results were obtained in
DU145 prostate cancer cells previously shown to scavenge amino
acids via necrocytosis (ref. 3 and Supplementary Fig. 2a–c).
Blocking macropinocytosis with EIPA prevented the transfer of
HPG from necrotic cell debris into the macropinocytic MCF-7
proteome (Fig. 2g, h). Blocking protein synthesis with cyclohex-
imide resulted in a diffuse cytosolic staining pattern in MCF-7
and DU145 cells fed HPG-labeled necrotic debris confirming that
new protein synthesis was required for HPG labeling of nuclear
and cytosolic proteins in macropinocytic cells (Fig. 2g, h and
Supplementary Fig. 2b, c). Non-macropinocytic HCC1569 breast
cancer cells did not incorporate HPG from necrotic debris even
when the incubation period was extended to 24 h (Fig. 2h, i). In
summary, a clickable amino acid tracer can be used to monitor
macropinocytic flux and confirmed that nutrient-deprived,
macropinocytic breast cancer cells can fuel new protein synthesis
with proteins scavenged from dead cell corpses.
Necrocytosis provides access to carbohydrates. Several studies
have demonstrated that amino acids can be scavenged from
macropinocytosed proteins3,4,8,9,25. However, provided that a
macromolecule can be broken down in the lysosome and the
subunits exported to the cytosol, necrotic cell debris contains all
of the building blocks necessary to produce a new cell. Cancer
cells import and oxidize glucose to generate ATP, but glucose
is also funneled into the hexosamine biosynthesis pathway to
produce N-acetylglucosamine (GlcNAc) required for protein
O-GlcNAcylation reactions26. To assess whether GlcNAc, and
potentially other carbohydrates, can be scavenged via necrocy-
tosis, FL5.12 cells were labeled with a clickable, alkynyl form of
GlcNAc, tetraacylated N-(4-pentynoyl)-glucosamine (Ac4Glc-
NAlk) (Supplementary Fig. 3a)27. The acetyl groups on Ac4Glc-
NAlk increase the membrane permeability of this unnatural sugar
but are removed by carboxyesterases in the cytosol, generating the
monosaccharide. FL5.12, MCF-7, and HCC1569 cells all labeled
efficiently with free Ac4GlcNAlk, producing labeling patterns
consistent with the wide range of membrane, cytosolic, and
nuclear proteins that undergo O-GlcNAcylation (Supplementary
Fig. 3a, b)28. Macropinocytic MCF-7 breast cancer cells, but not
non-macropinocytic HCC1569 cells, were able to recover
GlcNAlk from labeled necrotic cell debris, producing a staining
pattern similar to that observed upon free Ac4GlcNAlk addition
(Supplementary Fig. 3b–e). Blocking macropinocytosis with EIPA
significantly reduced GlcNAlk flux from necrotic debris into
MCF-7 cells (Supplementary Fig. 3c, d). As EIPA completely
blocked HPG incorporation from labeled necrotic debris under
similar experimental conditions (Fig. 2g, h), MCF-7 cells may
secrete enzymes that liberate free GlcNAlk from necrotic debris.
Because non-macropinocytic HCC1569 breast cancer cells did
not label when incubated with GlcNAlk-labeled necrotic cell
debris (Supplementary Fig. 3d, e), enzymes that release free
GlcNAlk are not present in the necrotic debris itself. The ability
to scavenge carbohydrates may contribute to the ability of mac-
ropinocytic MCF-7 and T-47D, but not non-macropinocytic
HCC1569, cells to proliferate in medium deficient in both amino
acids and glucose (1% AA/gluc) in the presence of necrotic debris
(Supplementary Fig. 3f, g). As expected, blocking necrocytosis
with EIPA eliminated this proliferation. In summary, sugars can
be scavenged from necrotic material via macropinocytosis.
Necrocytosis relieves dependence on fatty acid synthesis. While
necrocytosis preserves lipid droplets in nutrient-restricted pros-
tate cancer cells3, it was not clear whether lipids can be directly
scavenged from cell corpses or whether scavenging of other
nutrients simply reduces ATP demand and, consequently, lipid
catabolism in the macropinocytic cell. To directly monitor lipid
flux from necrotic cell debris into macropinocytic breast cancer
cells, FL5.12 cells were labeled with alkynyl palmitate, a fatty acid
used for fatty acid oxidation, post-translational protein mod-
ifications, and to build cell membranes29. FL5.12, MCF-7, and
HCC1569 cells labeled efficiently with free alkynyl palmitate
(Fig. 3a, b). Similar to results with HPG and GlcNAlk (Fig. 2 and
Supplementary Fig. 3), macropinocytic MCF-7, but not non-
macropinocytic HCC1569, breast cancer cells recovered alkynyl
palmitate from labeled necrotic debris (Fig. 3c, d and Supple-
mentary Fig. 4a). Inhibiting macropinocytosis with EIPA elimi-
nated labeling in MCF-7 cells confirming that macropinocytosis
was required. Thus, necrocytosis provides macropinocytic breast
cancer cells with fatty acids at what should be physiologic ratios.
Fatty acid synthesis is critical for tumor cell growth14,30.
Fatty acid synthase (FASN) is over-expressed in some breast
tumors and FASN inhibition limits breast tumor growth31. As
macropinocytic breast cancers can scavenge fatty acids from
necrotic cell debris (Fig. 3c, d), necrocytosis may reduce
dependence on FASN and thus sensitivity to FASN inhibi-
tors (FASNi). The FASNi GSK219406932 killed MCF-7 cells
and slowed the proliferation of HCC1569 breast cancer cells
(Fig. 3e, f). Consistent with the proposal that fatty acid
scavenging would reduce dependence on FASN, supplementa-
tion with necrotic cell debris rescued macropinocytic MCF-7,
but not non-macropinocytic HCC1569, breast cancer cells from
GSK2194069. While MCF-7 cells were also rescued from
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GSK2194069 by supplementation with free fatty acids as
expected, HCC1569 cells were not (Supplementary Fig. 4b).
However, contextually macropinocytic MDA-MB-468 cells were
rescued from FASN inhibition by free fatty acids, but not necrotic
debris, validating this approach (Supplementary Fig. 4c, d).
Prostate cancers both over-express FASN and depend on fatty
acid uptake33; blocking either process limits prostate cancer cell
growth and survival. PTEN-deficient prostate cancers (e.g.,
LNCaP) are macropinocytic3, while PTEN-replete 22Rv1 prostate
cancer cells are not (Fig. 3g). Both LNCaP and 22Rv1 prostate
cancer cells died when exposed to the FASNi GSK2194069 and
were rescued by free fatty acids (Fig. 3h, i and Supplementary
Fig. 4e, f). Similar to results with breast cancer cells, macro-
pinocytic LNCaP cells, but not non-macropinocytic 22Rv1 cells,
were also rescued from FASN inhibition by supplementation with
necrotic cell debris (Fig. 3h, i). These results demonstrate that
necrocytosis provides fatty acids and affords resistance to
therapeutics that limit lipid biosynthesis.
Necrocytosis can supplant nucleotide biosynthesis. Nucleotide
synthesis represents a metabolic bottleneck for rapidly proliferating
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cancer cells14. Amino acids derived from macropinocytosed pro-
teins could be used to support nucleotide synthesis. Alternatively,
directly scavenging nucleotides via necrocytosis would avoid ener-
getically demanding nucleotide biosynthesis. When the alkynyl
thymidine analog 5-ethynyl-2-deoxyuridine (EdU)34 was added to
the culture medium, it was readily incorporated into the genomic
DNA of FL5.12, MCF-7, and HCC1569 cells as expected (Fig. 4a,
b). Akin to results obtained with HPG, GlcNAlk, and alkynyl pal-
mitate, macropinocytic MCF-7 cells, but not non-macropinocytic
HCC1569 cells, were able to recover EdU from necrotic cell debris
(Fig. 4c–e). Blocking macropinocytosis with EIPA prevented the
transfer of EdU from necrotic cell debris to MCF-7 cells, again
implicating macropinocytosis in this process. Blocking DNA
replication with hydroxyurea35 also eliminated the nuclear EdU
signal in MCF-7 cells, confirming that EdU was incorporated into
genomic DNA. In sum, macropinocytic cells can recover nucleo-
tides directly from necrotic debris.
Many standard-of-care cancer therapies target nucleotide
biosynthesis directly or indirectly36,37. Agents such as 5-
fluorouracil (5-FU) and gemcitabine block nucleotide biosynth-
esis, while DNA damaging agents (e.g., doxorubicin or ionizing
radiation) increase dependence on nucleotide synthesis due to the
need for DNA repair. Many different solid tumors initially
respond to genotoxic chemotherapies, but resistance frequently
develops. Metabolic adaptations include the up-regulation of de
novo nucleotide synthesis pathways, increased nutrient import,
and recycling via autophagy15,38,39. By providing breast cancer
cells with scavenged nucleotides (Fig. 4), necrocytosis may also
contribute to resistance to cancer therapies that deplete nucleo-
tide pools. Breast cancer is treated with 5-FU, a pyrimidine analog
that inhibits thymidylate synthase40. Both MCF-7 and HCC1569
cells were sensitive to 5-FU (Fig. 5a, b). Supplementation with
necrotic cell debris afforded striking protection to 5-FU-treated
macropinocytic MCF-7 cells, restoring proliferation to the level
seen in untreated cells. As necrotic cell debris did not protect
HCC1569 cells, the debris is not simply reducing toxicity by
sequestering 5-FU. As expected, EIPA eliminated the ability of
necrotic debris to rescue MCF-7 cells from 5-FU, and supplying
the thymidine precursor deoxythymidine monophosphate
(dTMP) rescued both macropinocytic and non-macropinocytic
breast cancer cells from 5-FU (Supplementary Fig. 5a–c). Like 5-
FU, gemcitabine blocks nucleotide synthesis, but does so by
inhibiting ribonucleotide reductase40. Gemcitabine is a standard-
of-care treatment for pancreas cancer, a tumor type that is
frequently macropinocytic. Gemcitabine killed both macropino-
cytic PANC-1 and non-macropinocytic BxPC3 cells (Fig. 5c, d).
Supplementation with necrotic cell debris fully restored pro-
liferation in PANC-1 cells while failing to benefit BxPC3 cells that
are incapable of necrocytosis3. Thus, necrocytosis affords
dramatic protection from standard-of-care chemotherapies that
target nucleotide synthesis pathways.
DNA damaging agents like the topoisomerase inhibitor
doxorubicin, increase the demand for nucleotide synthesis15.
Doxorubicin triggered cell death in MCF-7, MDA-MB-231, and
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HCC1569 breast cancer cells (Fig. 5e, f). Necrotic cell debris
prevented death in both of the macropinocytic cell lines, MCF-7
and MDA-MB-231, while non-macropinocytic HCC1569 cells
remained fully sensitive to doxorubicin. Murine 4T1 mammary
carcinoma cells were sensitive to γ-irradiation (Fig. 5g). Radiation
has been reported to increase AMPK activation41,42, and
γ-irradiation stimulated macropinocytosis in both 4T1 and
MDA-MB-468 cells maintained in complete medium (Fig. 5h).
Consistent with the stimulation of macropinocytosis by γ-
irradiation (Fig. 5h), supplementation with necrotic cell debris
allowed irradiated 4T1 breast cancer cells to proliferate in an
EIPA-sensitive manner (Fig. 5g). Interestingly, 5-FU treatment
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was also sufficient to stimulate macropinocytosis in contextually
macropinocytic 4T1 and MDA-MB-468 breast cancer cells
(Fig. 5h), and necrotic cell debris rendered both cell lines
resistant to 5-FU (Fig. 5i, j). Microtubule-stabilizing agents do not
kill cancer cells by inducing metabolic stress. Consistent with this,
necrocytosis did not protect macropinocytic LNCaP cells from
docetaxel-induced death (Supplementary Fig. 5d, e). Together,
these findings demonstrate that necrocytosis can render cancer
cells resistant to a variety of metabolic cancer therapies by
providing the end products of biosynthesis.
Macropinocytosis confers resistance to chemotherapy in vivo.
While necrocytosis supported cancer cell proliferation and pro-
vided resistance to metabolic chemotherapies in vitro, it was
unclear whether viable cells in the tumor microenvironment
would have sufficient access to dead cells or other high-quality
macropinocytic fuel to drive tumor growth or drug resistance. We
first considered whether EIPA could be used to dissect the con-
tribution macropinocytosis makes to tumor growth. However,
EIPA completely blocked the proliferation of non-macropinocytic
breast, prostate, and pancreas cancer cells in complete medium
containing abundant nutrients (Fig. 6a and Supplementary
Fig. 6a). These results are consistent with EIPA’s significant,
macropinocytosis-independent anti-proliferative effects43. Selec-
tive, genetic approaches have enabled landmark studies dissecting
the role of autophagy in tumor initiation and progression44. In
contrast, no proteins have been identified that function only in
macropinocytosis, precluding replacing EIPA with a genetic
knockout strategy. However, a double point mutant of the actin
capping protein regulator CARMIL1, CARMIL1 KR987/989AA
(CARMIL1-AA), supports normal RAC GTPase activation and
cell migration, but not macropinocytosis45. CARMIL1-AA is not
a dominant-negative mutant, and thus the endogenous CARMIL1
protein must be knocked down to observe macropinocytosis
inhibition. As expected, reconstituting 4T1 CARMIL1 knock-
down cells with an shRNA-resistant cDNA encoding wild type
CARMIL1 (CARMIL1-WT), but not mutant CARMIL1-AA,
restored macropinocytosis in response to both nutrient depriva-
tion and 5-FU (Fig. 6b, c and Supplementary Fig. 6b). Impor-
tantly, CARMIL1-WT and CARMIL1-AA 4T1 cells proliferated
equally well in complete medium where neither is macropinocytic
(Fig. 6d and Supplementary Fig. 6c). However, CARMIL1-AA
cells were unable to use necrocytosis to fuel proliferation in low-
nutrient medium or in the presence of 5-FU (Fig. 6d, e and
Supplementary Fig. 6c, d). Together, these results demonstrate
that replacing endogenous CARMIL1 with the CARMIL1-AA
mutant blocks macropinocytosis-driven proliferation more
selectively than does the commonly used macropinocytosis
inhibitor, EIPA.
CARMIL1-WT and CARMIL1-AA 4T1 cells were employed to
measure the contribution macropinocytosis makes to tumor
growth in vivo. Consistent with in vitro assays (Fig. 6b),
orthotopic, syngeneic tumors formed from CARMIL1-WT, but
not CARMIL1-AA, 4T1 cells were macropinocytic (Fig. 7a). Non-
macropinocytic CARMIL1-AA tumors took longer to reach a
volume of 100 mm3, and a subset of CARMIL1-AA tumors grew
more slowly that macropinocytosis-competent CARMIL1-WT
tumors (Fig. 7b, c and Supplementary Fig. 7a). These differences
translated into a significant survival benefit for mice bearing
CARMIL1-AA tumors (Fig. 7d). 4T1 tumors exhibit rapid growth
and were highly necrotic as expected (Supplementary Fig. 7b).
Necrotic cells were distributed throughout the tumor suggesting
that necrotic debris is readily accessible to viable 4T1 tumor cells.
Given that necrotic cell debris, but not 5% albumin, is sufficient
to promote 4T1 cell proliferation in low nutrients in vitro
(Supplementary Fig. 7c), it is likely that necrocytosis accounts for
the more robust growth of CARMIL1-WT tumors in vivo
(Fig. 7b–d). Because CARMIL1-AA is more selective than EIPA
(Fig. 6a, d and Supplementary Fig. 6a, c), these tumor growth
assays also provide more rigorous support for the model that
macropinocytosis drives solid tumor growth than published
studies using EIPA3,4,8.
Whether necrocytosis could protect tumors from 5-FU was
next assessed. In vitro, macropinocytic CARMIL1-WT, but not
non-macropinocytic CARMIL1-AA, 4T1 cells were resistant to 5-
FU selectively in the presence of necrotic debris (Fig. 6e and
Supplementary Fig. 6d). Importantly, 5% albumin did not rescue
from 5-FU (Supplementary Fig. 7d). To evaluate whether
necrocytosis provided resistance to chemotherapy in vivo,
CARMIL1-WT or CARMIL1-AA tumors were treated with
30 mg/kg 5-FU every 3 days for 3 doses once each tumor reached
100 mm3. During the 5-FU treatment period, the average volume
of CARMIL1-AA tumors did not increase while CARMIL1-WT
tumors continued to grow (Fig. 7e and Supplementary Fig. 7e).
Upon termination of 5-FU treatment, tumor growth resumed,
although at a slower rate for 5-FU-treated CARMIL1-AA than
CARMIL1-WT tumors. This difference in response resulted in
a significantly extended survival time in 5-FU-treated mice
bearing CARMIL1-AA tumors relative to both 5-FU-treated
mice bearing CARMIL1-WT tumors and to vehicle-treated mice
bearing CARMIL1-AA tumors (Fig. 7f). Taken together, these
results provide strong evidence that necrocytosis can render
macropinocytic tumor cells resistant to standard-of-care therapies
that target biosynthetic pathways.
Discussion
Many tumor cells are likely macropinocytic. Activation of the
RAS and PI3 kinase pathways is common across cancer classes
and has been shown to drive macropinocytosis in pancreas, lung,
colorectal, bladder, prostate, and now breast cancer cells3,4,19,46
(Fig. 1a). Importantly, the rate of macropinocytic flux in breast
cancer cells is sufficient to support proliferation in nutrient-
Fig. 5 Necrocytosis confers resistance to standard-of-care therapies that target or create dependence on nucleotide biosynthesis. a Proliferation of
macropinocytic MCF-7 or non-macropinocytic HCC1569 cells ± 5-FU (30 μM) ± necrotic debris (0.2% protein) at 96 h. b Representative bright field
images for proliferation assay in a. c Proliferation of macropinocytic PANC-1 or non-macropinocytic BxPC-3 cells ± necrotic debris (0.2% protein) ±
gemcitabine (20 μM) at 96 h. d Representative bright field images for proliferation assay in c. e Proliferation of macropinocytic MCF-7 and MDA-MB-231
or non-macropinocytic HCC1569 cells ± doxorubicin (1 μM) ± necrotic debris (0.2% protein) at 72 h. f Representative bright field images for proliferation
assay in e. g Proliferation of 4T1 cells in CM subjected to 5 Gy of γ-irradiation ± nec cells and ± EIPA (10 μM) at 72 h. h Dextran uptake in 4T1 or MDA-MB-
468 cells 2 h after γ-irradiation (2 Gy) or 1 h after treatment with 5-FU (5 μM). Statistics compare dextran index (in white) in control and irradiated or
treated cells; 30 cells from two independent experiments were evaluated. Using a one-way ANOVA and Dunnett’s correction, ***P≤ 0.001. i Proliferation
of 4T1 or MDA-MB-468 cells ± 1 μM (4T1) or 20 μM (MDA-MB-468) 5-FU ± necrotic debris (0.2% protein) at 72 h (4T1) or 96 h (MDA-MB-468).
j Representative images for i (duplicate wells shown). In a, c, e, g and i, mean ± SD shown, n= 3; Using a one-way ANOVA and Tukey’s correction, *P ≤
0.05; ***P ≤ 0.001; ns, not significant, P > 0.05.
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limiting conditions provided that necrotic corpses are supplied as
fuel (Fig. 1c and Supplementary Fig. 3f). Albumin can support the
proliferation of some macropinocytic cells in low glutamine or
when non-essential amino acids are limiting4,10, but was not
sufficient to support breast cancer cell proliferation in media
generally deficient in amino acids, in both amino acids and glu-
cose, or in cells exposed to 5-FU (Fig. 1c and Supplementary
Figs. 3f and 7c, d). As necrotic cell debris supported proliferation
in these same conditions even when provided at a 25-fold lower
concentration than albumin, necrotic cell debris is a much higher
quality macropinocytic fuel source. These results highlight that
in vitro experiments where only BSA is supplied as fuel are likely
to underestimate the potential contribution of macropinocytosis
to tumor cell anabolism. At the same time, it is difficult to
determine what a physiologically relevant amount of necrotic cell
debris would be. Dead cells are present throughout tumors, not
just in large, necrotic foci, and comprise a significant fraction of
the tumor volume (e.g., 70–80% in Supplementary Fig. 7b). It has
been reported that triggering apoptosis paradoxically promotes
tumorigenesis by stimulating the proliferation of neighboring
viable cells47. This death-driven proliferation may be fueled in
part by necrocytosis; when apoptotic cells undergo secondary
necrosis, “bite-sized” fragments are created. Co-injection of dead
cells with viable 4T1 cells accelerates their proliferation in
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subcutaneous tumor models48, a result consistent with Fig. 7a–c.
Most solid tumors, including breast cancers, contain necrotic
areas, and evidence of tumor necrosis correlates with poor
prognosis13,49–51. Our results with CARMIL1-AA 4T1 tumors
provide compelling evidence that necrocytosis can make a sig-
nificant contribution to tumor anabolism (Fig. 7 and Supple-
mentary Fig. 7) and help to explain paradoxical observations that
tumor cell death drives tumor growth.
Prior to this report, macropinocytosis had only been docu-
mented to provide amino acids3–5,8–10,46,52. While necrocytosis
can maintain lipid droplet content in amino acid-deprived prostate
cancer cells3, whether this occurred because protein scavenging
decreased the need for lipid droplet catabolism or because necrotic
cell debris supplied lipids was unclear. Click chemistry-based flux
analysis now confirms that many macromolecules, not just amino
acids, can be recovered via necrocytosis. Extracellular proteins are
often glycosylated; many macropinocytosed proteins would carry
sugars that could be recycled. Carbohydrate scavenging (Supple-
mentary Fig. 3c, d) could spare glucose that would otherwise be
required for glycosylation and stimulate pro-growth signal trans-
duction and transcription. For example, GlcNAc synthesis is
important for the expression of growth factor receptors that are
critical for breast cancer cell proliferation and survival53,54. Fatty
acids were also scavenged from necrotic cell debris via macro-
pinocytosis (Fig. 3c, d). Fatty acids can be oxidized, used for
membrane synthesis, or support signaling in growing cancer cells.
Fatty acid synthesis is particularly important in breast and prostate
cancer cells, and fatty acids synthase inhibitors are in clinical
trials30,31. The effectiveness of the FASNi GSK2194069 against
breast and prostate cancer cells was significantly compromised if
macropinocytic cells had access to necrotic cell debris (Fig. 3e–i); if
fatty acids can be scavenged from the tumor microenvironment,
cells will no longer be dependent on FASN. In sum, necrocytosis is
likely to decrease the effectiveness of a wide range of drugs tar-
geting tumor anabolism by providing the end products of bio-
synthesis. Pairing these metabolic therapies with macropinocytosis
inhibitors may increase the depth of the response and limit the
development of resistance.
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(n= 26) or CARMIL1-AA cells (n= 25); tumor volume was measured with calipers daily starting on day 6. Using an unpaired, two-tailed t test, ***, P ≤
0.001, mean ± SEM. c Growth of the tumors in b. d Kaplan–Meier survival analysis in mice bearing CARMIL1-WT (n= 12) or CARMIL1-AA (n= 11) 4T1
tumors. P-value calculated using a two-sided log-rank (Mantel-Cox) test. e As in b, but animals were treated with vehicle (CARMIL1-WT, n= 12; CARMIL1-
AA, n= 11) or 30mg/kg 5-FU (CARMIL1-WT, n= 12; CARMIL1-AA, n= 12); mean ± SEM. Yellow triangles mark days 5-FU was administered. Statistics
compare CARMIL1-WT vs. CARMIL1-AA tumors treated with 5-FU (black asterisks) or CARMIL1-AA tumors treated with vehicle or 5-FU (red asterisks).
Using a one-way ANOVA and Tukey’s correction, *P≤ 0.05; **P≤ 0.01; ***P≤ 0.001; no asterisk, P > 0.05. f Kaplan–Meier survival curve beginning after
initiation of 5-FU treatment. P-value calculated using a two-sided log-rank (Mantel-Cox) test and compare 5-FU-treated CARMIL1-WT (n= 12) and
CARMIL1-AA tumors (n= 11) in black or CARMIL1-AA tumors treated with vehicle (n= 12) or 5-FU (n= 12) in red.
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Therapeutic resistance is a major barrier to effective cancer
therapy, particularly in patients with aggressive tumors (e.g.,
pancreas, prostate, and triple-negative breast cancer) where
mutations that drive macropinocytosis are common. In keeping
with the results presented here (Figs. 5 and 7), patients bearing
tumors with PIK3CA or KRASmutations or with decreased PTEN
activity are more likely to be resistant to chemotherapy55–58.
There is also a strong link between tumor necrosis and ther-
apeutic resistance across tumor classes. Necrosis would provide
high-quality macropinocytic fuel, reducing dependence on
nucleotide biosynthesis pathways that are a known therapeutic
liability14,15,59,60. It is particularly striking that the nucleotide
synthesis inhibitors 5-FU and gemcitabine were ineffective if cells
were able to perform necrocytosis (Figs. 5a–d, i, and j, 6e and
Supplementary Fig. 6d) translating into significant therapeutic
resistance in macropinocytic tumors in vivo (Fig. 7e, f and Sup-
plementary Fig. 7e). This result is reminiscent of recent reports
that deoxycytidine release from macrophages also limits the
effectiveness of gemcitabine61. The effectiveness of genotoxic
therapies such as doxorubicin and γ-irradiation that create
dependence on de novo nucleotide synthesis pathways15,62 was
also compromised by necrocytosis (Fig. 5e–g). Genotoxic thera-
pies and radiation are standard-of-care treatments for many
cancer classes that are likely to be macropinocytic. Moreover,
therapy may induce macropinocytosis in some tumors (Fig. 5h).
Glioblastomas, a cancer class with a dismal long-term survival
rate even with therapy, often have PTEN or PIK3CA mutations,
AMPK activation, and large areas of necrosis at diagnosis63,64.
Both radiation and temozolomide, an alkylating agent, are first
line treatments; necrocytosis may play an important role in
therapeutic resistance in glioblastoma patients. In summary,
when used in combination with radiation and standard-of-care
chemotherapy, macropinocytosis inhibitors have the potential to
produce significant gains in survival in patients with lethal,
aggressive cancers.
The contribution that macropinocytosis makes to cancer cell
anabolism and therapeutic resistance has likely gone unrecog-
nized in part due to the conditions under which in vitro
experiments are generally performed. Standard tissue culture
media are largely bereft of macropinocytic fuel, containing
only limited amounts of albumin (10% serum provides ~0.3%
albumin3). In contrast, the tumor microenvironment is rich in
macromolecules and debris that are ripe for scavenging (Sup-
plementary Fig. 7b). Indeed, macropinocytosis may provide one
explanation why discrepant results are obtained when metabolic
inhibitors are used in vitro and in vivo65. An additional trans-
lational implication of this study is that the clinical benefits of
autophagy inhibitors that block lysosomal degradation (e.g.
chloroquine derivatives66,67) may be derived as much from
blocking macropinocytic flux as from autophagy inhibition. If so,
the biomarkers selected to identify sensitive patients and confirm
therapeutic efficacy would need to be reconsidered. Given the
accumulating evidence that many tumor classes are macro-
pinocytic and the clear anabolic benefits of scavenging, it is very
likely that macropinocytosis makes as large a contribution to
therapeutic resistance as does autophagy. Although additional
studies will be required to fully assess the selectivity of the
CARMIL1-AA mutant for macropinocytosis among other actin
dependent processes, CARMIL1-AA is currently the only che-
mical or genetic approach to blocking macropinocytosis that
preserves normal proliferation in non-macropinocytic cells. By
offering a more selective means to disable macropinocytosis in
tumor cells than EIPA (Fig. 6), the CARMIL1-AA mutant will
facilitate future studies evaluating the role of macropinocytosis in
tumor growth and progression.
Methods
Cell lines and cell culture. All cultured cells were maintained at 37 °C in 5% CO2.
All media were supplemented with 10% standard fetal bovine serum and antibiotics
unless otherwise stated. MDA-MB-231, MDA-MB-468, MCF-7, T-47D, BT-549,
Hs578T, HCC1569, hTERT-HME1 PANC-1, BxPC3 and LNCaP, cells were
obtained from the ATCC. The 4T1 cell line was provided by Jennifer Prescher (UC
Irvine) and MCF10A PIK3CA knock-in cells20 were supplied by Ben Ho Park
(Johns Hopkins School of Medicine); both 4T1 and MCF10A cells were originally
purchased from the ATCC. 22Rv1 cells were provided by Ionis Pharmaceuticals
(Carlsbad, CA). hTERT-HME1 were cultured without serum in MEGM base
medium supplemented additives provided in the MEGMTM BulletKitTM medium.
MCF10A cells were cultured in DMEM/F12 Ham’s Mixture without phenol red
and supplemented with 5% horse serum, EGF (20 ng/ml), insulin (10 mg/ml),
hydrocortisone (0.5 mg/ml), cholera toxin (100 ng/ml), 1% penicillin and strepto-
mycin. MDA-MB-231, MDA-MB-468, and PANC-1 cells were cultured in DMEM
with L-glutamine, 4.5 g/L glucose and without sodium pyruvate and supplemented
with 1% sodium pyruvate. MCF-7 cells were cultured in RPMI supplemented with
1% L-glutamine. LNCaP, HCC1569, 22Rv1, and BxPC3 cells were cultured in
RPMI-ATCC modified medium. T-47D and BT-549 cells were cultured in RPMI-
ATCC modified medium with 0.2 or 0.023 IU/ml bovine insulin, respectively. 4T1
were cultured in DMEM with L-glutamine, 4.5 g/L glucose and without sodium
pyruvate. Hs578T were cultured in the same medium as 4T1 but supplemented
with 15% FBS and 0.01 μg/ml insulin. FL5.12 cells were maintained in RPMI 1640
medium supplemented with 10 mM HEPES, 55 μM β-mercaptoethanol, antibiotics,
2 mM L-glutamine, and 500 pg/ml murine rIL-3. PIK3CAH1047R and PIK3CAE545K
MEFs were produced by transduction of p53−/− MEFs (generated in house) using
pBabe-puro-HA-PIK3CAH1047R or -PIK3CAE545K (a gift from Jean Zhao, Addgene
plasmids #12524 and #12525)68. All cells were passaged for ≤3 weeks at which
point low-passage vials were thawed. Mycoplasma testing was performed using the
VENOR GeM PCR kit every 4–6 months for all cell lines. Before use in these
experiments, 4T1 cells were cured of Mycoplasma by culturing in ciprofloxacin for
8 wks; cure was confirmed by two serial PCR tests. All CARMIL1 reagents were
obtained from John Cooper (Washington University). pFLRu-CARMIL1 shRNA-
#1968 was used to knockdown endogenous CARMIL1 as described in ref. 69
(targeting sequence ATGCCATTGTTCATCTGGAT). A non-targeting shRNA
(Addgene plasmid #1864, hairpin sequence CCTAAGGTTAAGTCGCCCTCGC
TCGAGCGAGGGCGACTTAACCTTAGG) was used as a negative control as
described in ref. 70. Knockdown of endogenous CARMIL1 in 4T1 was validated by
qRT-PCR (Forward primer: 5′-GAGCTGAGGTCAGGAGGAGC-3′ and Reverse
primer: 5′-TTTTGCCCAATGCCAGGTGC-3′). shRNA-resistant cDNAs expres-
sing wild type CARMIL1 (pFLRu-CARMIL1-WT shRNA-#1969) and CARMIL1
KR987/989AA (pFLRu-CARMIL1-AA shRNA-#1970) were introduced into 4T1
CARMIL1 knockdown cells, and clones selected. shRNA-resistant human CAR
MIL1 was cloned using Forward primer: 5′- GCCGAATTCAATGACCGAGGA
GAGCTCTGACGTTC-3′ and Reverse primer: 5′- GCCGGATCCTTACACAA
AAATAAACTCTTTTTC-3′69. Four to eight independent clones were screened in
dextran uptake assays with similar results. Experiments conducted with two
representative clones are shown.
Microscopy. Fluorescence microscopy was performed on either a Yokogawa
spinning disk confocal microscope using a ×100 oil objective (dextran and CFSE-
labeled FL5.12 uptake assays) or ×40 water objective with ×1.5 magnification (click
chemistry and in vivo Ficoll uptake). Open source software micro-manager (ver-
sion 2.0) was used to acquire images obtained with the spinning disk confocal. A
Nikon Eclipse-Ti2000 inverted microscope was used for bright field imaging. All
live confocal imaging (dextran or CFSE-labeled FL5.12 uptake assays) was per-
formed at 37 °C. Z-stacks were collected with step size of 0.5 microns and
8–10 stacks were obtained from 20 to 40 independent fields. 5-FU-stimulated
dextran uptake in Fig. 5 and all dextran uptake assays in Fig. 6 were performed in
fixed cells and evaluated on a Zeiss LSM 780 confocal microscope using Zeiss Zen
2.3 image acquisition software. Microscope acquisition settings were held constant
within each experiment and determined for each experiment using positive and
negative controls. H&E sections were imaged using a Nikon Ti2-F inverted epi-
fluorescence microscope equipped with a DS-Fi3 color camera (whole tumor
sections) and a AmScope compound microscope with a Aptina MT9P031 color
camera (high magnification).
Dextran uptake assays. Cells were seeded into 8-chamber slides (Cellvis, cat# C8-
1.5H-N) 12–16 h before uptake assays. Cells were subjected to nutrient stress for
16 h prior to dextran uptake assays. MEM or RPMI containing 1% of the normal
amount of amino acids and/or glucose (1% AA or 1% AA/gluc medium) was
produced by preparing DMEM or RPMI lacking amino acids and/or glucose from
chemical components and mixing it 99:1 with complete medium. Cells were
incubated with 70 kD Oregon Green fluorescent dextran (1 mg/ml), 70 kD Texas
Red fluorescent dextran (1 mg/ml), Lysotracker Red (500 nM) and Hoechst 33342
(1 µg/ml) for 30 min, washed three times with PBS, and fresh culture medium
added. Drug pre-treatment and concentrations were as follows: EIPA, 50 µM, 1.5 h
pre-treatment; PMA, 250 nM, co-addition with dextran; A769662, 50 µM, 1.5 h
pre-treatment. Dextran uptake assays were performed 2 h after irradiation (2 Gy).
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Generation and uptake of necrotic and apoptotic cells. Apoptotic FL5.12 cells
were generated by withdrawing IL-3 from cells maintained at a density of 1 mil-
lion/ml for 24 h. Necrotic cell debris was collected after 72 h of IL-3 withdrawal
from cells maintained at 10 million/ml. Where indicated, FL5.12 cells were labeled
with 5 μM CFSE at 500,000 cells/ml in PBS containing 1% FBS and 500 pg/ml IL-3
for 30 min. One million necrotic or apoptotic CFSE-labeled cell equivalents were
spun down in a microfuge at 9000 × g at 4 °C for 10 min, the supernatant discarded,
and the pelleted debris added to nutrient-deprived (1% AA/gluc for 16 h) mac-
ropinocytic breast cancer cells for 1 h. Where indicated, breast cancer cells were
pre-treated with EIPA (50 μM) for 1.5 h. Cells were imaged live in fresh culture
medium after 4–6 washes with PBS to remove any remnants of apoptotic or
necrotic cells.
Proliferation assays. Cells at 60% confluence (12–16 h after seeding in a 24 well
plate) were washed twice with PBS then incubated in 1% AA or 1% AA/gluc
medium and supplemented with 10 million necrotic cell equivalents (0.2% protein),
10 million apoptotic cell equivalents (1% protein), or 5% fatty acid free BSA. The
degree of nutrient stress was selected based on nutrient titration experiments
demonstrating a 50% reduction in cell viability at 48 h. For proliferation assays in
Figs. 4 and 6, cells were treated when 30% confluent (12–16 h after seeding in a
24 well plate) with: FASNi GSK2194069 (20 µM), 5-FU (1–30 µM), gemcitabine
(20 µM), docetaxel (5 µM), or doxorubicin (1 µM) or subjected to γ-irradiation
(5 Gy). Treated cells were provided with 10 million necrotic cell equivalents (0.2%
protein) or left unsupplemented. For proliferation assays in Supplementary Figs. 4
and 5, GSK2194069-treated cells were supplemented with linoleic acid and oleic
acid (1 mg/ml) conjugated to 1% albumin. 5-FU treated cells were supplemented
with deoxythymidine monophosphate (1 µM). In Figs. 1c, g, 3e, h, 5a, c, 5e, g, and
Supplementary Figs. 3f, g and 5d, cell proliferation was determined by flow cyto-
metry by recording the number of cells that excluded vital dye (DAPI (1 mg/mL) or
PI (1 mg/mL)) over a fixed collection interval (30 s). The gating strategy used to
obtain live cell counts is illustrated in Supplementary Fig. 8. Representative bright
field images were obtained before cells were processed for flow cytometry. In
Figs. 5i, 6a, d, e, and Supplementary Figs. 4b, c, e, 5a, b, 6a, c, d, and 7c, d,
proliferation was measured using crystal violet assays. Cells were fixed in 4% PFA
for 15 min, stained with 0.05% crystal violet solution in PBS for 30 min, washed
three times with 1X PBS to remove excess dye, and allowed to dry for 16–24 h.
Crystal violet was recovered from cells using 100% methanol and absorbance at
595 nm measured using Gen5 version 5 microplate software reader.
Flux analysis using click chemistry. FL5.12 cells were labeled with 100 μM L-
homopropargylglycine hydrochloride (HPG), 500 μM alkynyl palmitic acid (alk-PA),
100 μM N-(4-pentynoyl)-glucosamine tetraacylated (Ac4GlcNAlk), or 1mM EdU for
24 h at a density of 10 million/ml. In FL5.12 cells, HPG labeling was performed in
methionine-free medium and alkynyl palmitic acid labeling was conducted in med-
ium containing 10% charcoal stripped serum. Necrosis was induced in labeled cells as
described above. Cancer cells (70% confluence in 8 chamber slides) were maintained
in 1% AAmedium for 16 h before 1 million cell equivalents of alkyne-labeled necrotic
debris was added for 24–48 h. Cells were washed 3–5 times with PBS, fixed in 4%
paraformaldehyde (10min, RT), washed twice with PBS, permeablized and blocked
(10% FBS and 0.3% Triton-X100 in PBS for 30min rocking at RT), and washed twice
with PBS. The click reaction (copper-catalyzed cycloaddition) was performed using
100 μM Tris [(1-benzyl-1H-1,2,3-triazol-4-yl)methyl] amine TBTA, 1mM sodium
ascorbate (made fresh each time), 100 μM CuS04 and 0.5mM biotin-azide in 100 μl
blocking solution for 1 h at 30 °C. After three washes with PBS, cells were incubated
for 1 h with Alexa488-streptavidin (1:1,000 in blocking solution), stained with DAPI
(1 mg/ml in PBS) for 10min, washed, and imaged in PBS. Drug concentrations and
pre-treatments were as follows: cycloheximide, 50 μg/mL (4 h); hydroxyurea, 10 mM,
(4 h); or EIPA, 50 µM (1.5 h).
In vivo experiments. All experiments in mice were performed in accordance with
protocols approved by the Institutional Animal Care and Use Committee of Uni-
versity of California, Irvine. To produce orthotopic tumors, 104 4T1 cells in 100 μl
PBS were injected into the 4th mammary fat pad of 3–4-week-old female BALB/c
mice. Twenty-three days after inoculation (tumor volume ≤ 1100mm3), 70 kD FITC-
Ficoll (1 mg dissolved in 1% Evan’s Blue Dye in normal saline) was injected intra-
tumorally 1 h after intraperitoneal (i.p.) injection of vehicle (DMSO) or 10mg/kg
EIPA. Mice were sacrificed 1 h after Ficoll injection, and tumors excised and frozen in
OCT. Sections (5–8/tumor) were prepared by the Pathology Research Services Core
Facility at UC Irvine, were fixed in 4% paraformaldehyde, stained with 1mg/mL
DAPI in PBS, washed twice with PBS, and mounted using Vectashield mounting
medium. To produce orthotopic tumors from CARMIL1-WT and CARMIL1-AA
4T1 cells, 5 × 104 cells were inoculated and evaluated as described above except that
FITC-Ficoll was delivered intravenously. Tumor volume was calculated using caliper
measurements and the formula, volume (mm3)= length [mm] × (width [mm])2 ×
0.52. Tumor volumes were measured every day once palpable. Once tumors reached
100mm3, animals were randomly assigned to either the vehicle (12% DMSO in PBS)
or 5-FU (30mg/kg administered intraperitoneally every third day for a total of three
treatments) group (n= 10–13). Mice were sacrificed once tumors reached 800mm3
or if signs of distress were detected. To evaluate tumor necrosis, CARMIL1-WT
tumors from three mice were fixed in Tissue-Tek® Xpress® Molecular Fixative
(Sakura) for 24 h after which tissues were paraffin embedded, sectioned (5 microns),
and stained with hematoxylin/eosin (H&E). Evaluation of necrosis was performed by
Experimental Tissue Resource core Director and board-certified pathologist, Dr.
Robert A. Edwards (UC Irvine).
Mouse husbandry. Female BALB/c mice obtained from Jackson Laboratory (stock
no. 000651) were maintained in autoclaved Envigo Teklab corncob (1/8th inch) under
SPF conditions and allowed to acclimate to laboratory conditions for at least 72 h prior
to use in experiments. Mice were housed in Techniplast individual ventilated cages (≤5
mice per cage) on ventilated racks at 21 ± 1 °C on a 12 h light/dark cycle. Animals were
fed Envigo Teklad 2020X global soy protein-free extruded rodent diet. Mice were
euthanized with CO2 followed by cervical dislocation per AVMA guidelines.
Image analysis. All image processing and analysis was performed using Image J
software (v2.0, NIH). Dextran and CFSE-necrotic or -apoptotic cell uptake was
quantified on a per cell basis, to determine the percent of cell area composed of
macropinosomes. Background subtraction was performed using a rolling ball
radius of 50 pixels. To segment macropinosomes, auto-thresholding was performed
until all macropinosomes were covered by the red thresholding signal. The same
thresholding values were applied across all cells within the experiment. Where
required, macropinosome segmentation was corrected manually to avoid over or
under compensation. The binary image was analyzed using the “analyze particles”
tool to retrieve the “area index”. For tumor samples, Ficoll uptake analysis was
performed on a per field rather than per cell basis. Maximum projections of z-
stacks were used for analysis and are shown in the figures. Microscopy data shown
in Figs. 1d, 2b, c, 3a, b, 4a, b and Supplementary Figs. 2a, 3a, b and 4a was not
quantified, representative images from two independent experiments are shown.
Statistical analysis and reproducibility. All statistical analysis was performed
using Graphpad Prism v7.0. In box plots, the center line is the median, the box is
delimited by the 25th to 75th percentile, and whiskers represent minimum and
maximum values. When two groups were compared, significance was determined
using a two-tailed, unpaired t test. When >2 groups were compared, a one-way
ANOVA was employed. Tukey’s method or Dunnett’s test was used to correct for
multiple comparisons where required. For survival curves, a two-sided Mantel-Cox
logrank test was applied. Mean ± SEM are shown unless otherwise indicated. *P ≤
0.05; **P ≤ 0.01; ***P ≤ 0.001, ns, not significant, P > 0.05. For all comparisons, actual
P-values are reported in the data source file that accompanies this manuscript.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this study are available within the paper, its
supplementary information files, and the source data file or available from the authors
upon request. A reporting summary for this article is available as a supplementary
information file.
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